MagForce signs distribution agreement with leading Russian medical device distribution company DELRUS
(Thomson Reuters ONE) -
MagForce AG /
MagForce signs distribution agreement with leading Russian medical device
distribution company DELRUS
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Market entry of NanoTherm® therapy in Russia expected for 2013; extension to
number of CIS states to follow
* DELRUS responsible for market approval in these territories
* First step for internationalization of NanoTherm® therapy
Berlin, Germany, May 22, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading
medical device company in the field of nanomedicine with focus on oncology, and
DELRUS Inc., a leading Russian medical device distribution company, announced
today the signing of a distribution agreement between the two companies.
Under the terms of the agreement DELRUS will be responsible for marketing
MagForce's NanoTherm® therapy in the Russian Federation, Belarus Republic,
Republic of Kyrgyzstan, Republic of Kazakhstan, Ukraine, Republic of Tajikistan
and Republic of Uzbekistan. DELRUS is also responsible for obtaining marketing
authorization of NanoTherm® therapy for the treatment of brain tumors in these
countries. The scope of the agreement will be extended to other tumor
indications upon an equivalent approval of the NanoTherm® therapy for example in
the EU.
"I am delighted to join forces with DELRUS to commercialize our innovative
NanoTherm® therapy in Russia and further CIS countries," said Dr Andreas Jordan,
Executive Board and Founder of MagForce. "DELRUS is one of the largest and most
established distributors for medical devices in Russia and the CIS, working with
many renowned medical devices manufacturers including Haemonetics, Terumo,
Stryker, Johnson & Johnson, Nihon Kohden, GE and Fresenius Kabi. Their extensive
distribution and service network as well as their excellent track record will
open up significant opportunities for introducing and supporting the usage of
our technology in these markets. In Russia alone it provides us access to about
6,000 brain tumor patients per year."
"DELRUS is committed to bring the most innovative and advanced technologies to
the Russian healthcare system. We are convinced that MagForce's technology has
great potential to provide "progress in the name of life," said July Magadeev,
President of DELRUS. "We look forward to the opportunity to introduce
nanomedicine in oncology to the medical market in Russia and further CIS
countries and professionally support its usage among oncology specialists and in
hospitals."
Within the framework of cooperation, the participation of Russian medical
centers is planned for conducting international clinical studies to expand the
scope of technology application for the treatment of other forms of cancer.
About MagForce AG
MagForce AG is a leading medical technology company in the field of nanomedicine
in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted
treatment of solid tumors through the intratumoral generation of heat via
activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and
NanoActivator(TM) are components of the therapy and have received EU-wide
regulatory approval as medical devices for the treatment of brain tumors.
MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG
in select countries. For more information, please visit www.magforce.com.
About DELRUS Inc.
DELRUS, founded in 1991 with currently more than 2500 employees, is an
international science and industry holding company maintaining partnership
relations with medical device manufacturers in 30 countries. The company, among
leaders in the Russian market for medical devices, is active in the supply of
medical institutions. DELRUS has regional affiliates in the 80 largest cities of
Russia, Belarus, Tajikistan, Kazakhstan, Kyrgyzstan, Uzbekistan, Azerbajan, and
the Ukraine. For more information please visit www.delrus.com/en.
About NanoTherm® Therapy
The NanoTherm® therapy is a new approach for the local treatment of solid
tumors. The principle of the method is the direct introduction of magnetic
nanoparticles into a tumor and their subsequent heating in an alternating
magnetic field. The water soluble nanoparticles are extremely small
(approximately 15 nanometers in diameter), and contain an iron oxide core with
an aminosilane coating. The particles are activated by a magnetic field that
changes its polarity 100,000 times per second and heat is produced. Depending on
the duration of treatment and the achieved intratumoral temperatures, the tumor
cells are either directly destroyed (thermal ablation) or sensitized for
concomitant chemo or radiotherapy (hyperthermia). With this new procedure, it is
possible to combat the tumor from the inside out, thereby sparing surrounding
healthy tissue. The nanoparticles remain in place at the treatment area,
allowing for repeat treatments and the integration of multimodal therapy
concepts. NanoTherm® therapy has regulatory approval in 27 European countries.
Disclaimer
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims", "anticipates",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-
looking statements are based on our current expectations and certain
assumptions, which may be subject to a variety of risks and uncertainties. The
results actually achieved by MagForce AG may substantially differ from these
forward-looking statements. MagForce AG assumes no obligation to update these
forward-looking statements or to correct them in case of developments, which
differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
Email: anne.hennecke(at)mc-services.eu
Press release:
http://hugin.info/143761/R/1613775/513982.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE
[HUG#1613775]
Unternehmensinformation / Kurzprofil:
Datum: 22.05.2012 - 08:34 Uhr
Sprache: Deutsch
News-ID 148677
Anzahl Zeichen: 7405
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MagForce signs distribution agreement with leading Russian medical device distribution company DELRUS"
steht unter der journalistisch-redaktionellen Verantwortung von
MagForce AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
